GlassScriptPhysician profile
Nathaniel Polnaszek
NPI 1932384872
$23,212.83
in general payments reported to CMS, 2019-2025
35 companies · $1,989 in 2025
The $1,989 reported for 2025 was more than what 80% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,316 · 2020: $13K · 2021: $1,470 · 2022: $2,002 · 2023: $1,260 · 2024: $2,056 · 2025: $1,989.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,842 · Travel and Lodging: $458 · Education: $5.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,842.07 |
| Travel and Lodging | $457.56 |
| Education | $5.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $13,144.71 | 2020-2024 | |
| Boston Scientific Corporation | $3,511.13 | 2019-2025 | Ams 700, Ams 800 Artificial Urinary Sphincter, Spaceoar Vue System - 10ml |
| Axonics, INC. | $1,184.57 | 2020-2024 | Axonics |
| Urogen Pharma, INC. | $533.04 | 2022-2025 | Jelmyto |
| Medtronic USA, INC. | $502.26 | 2019-2020 | |
| Calyxo, INC. | $486.45 | 2025 | Cvac Aspiration System |
| Teleflex LLC | $459.36 | 2021-2025 | Urolift |
| 180 Medical, INC. | $448.86 | 2019-2025 | Gentlecath Glide |
| Coloplast Corp | $405.59 | 2021-2025 | Speedicath |
| Astellas Pharma US INC | $327.01 | 2019-2022 | |
| Abbvie INC. | $271.43 | 2019-2025 | |
| Myriad Genetic Laboratories, INC. | $252.03 | 2021-2025 | Myrisk, Prolaris |
| Medtronic, INC. | $161.25 | 2021-2025 | Interstim |
| Palette Life Sciences, INC. | $154.71 | 2022 | |
| Clarus Therapeutics INC. | $152.63 | 2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $139.79 | 2019-2023 | Xiaflex, Aveed |
| Pfizer INC. | $127.70 | 2019-2021 | |
| Tolmar, INC. | $112.48 | 2024-2025 | Eligard, Jatenzo |
| Ferring Pharmaceuticals INC. | $101.36 | 2025 | Adstiladrin |
| Sumitomo Pharma America, INC. | $95.64 | 2023-2025 | Gemtesa |
| Allergan, INC. | $89.14 | 2021 | |
| Neotract INC. | $87.42 | 2019-2020 | |
| Becton, Dickinson and Company | $80.00 | 2022 | |
| Caldera Medical, INC | $61.97 | 2025 | |
| Conmed Corporation | $58.31 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $46.59 | 2025 | |
| Immunitybio, INC. | $41.45 | 2025 | |
| Procept Biorobotics Corporation | $33.08 | 2024 | Aquabeam System |
| Antares Pharma, INC. | $30.83 | 2024-2025 | Xyosted |
| Edap Technomed INC | $24.54 | 2020 | |
| Hollister Incorporated | $21.70 | 2024 | Vapro Pocket |
| Urovant Sciences INC | $20.93 | 2022 | |
| Travere Therapeutics, INC. | $15.43 | 2021 | |
| Cook Medical LLC | $14.79 | 2019 | |
| Endo USA, INC. | $14.65 | 2024 | Xiaflex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathaniel Polnaszek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.